ZA977263B - Treatment of upper airway allergic responses. - Google Patents

Treatment of upper airway allergic responses.

Info

Publication number
ZA977263B
ZA977263B ZA9707263A ZA977263A ZA977263B ZA 977263 B ZA977263 B ZA 977263B ZA 9707263 A ZA9707263 A ZA 9707263A ZA 977263 A ZA977263 A ZA 977263A ZA 977263 B ZA977263 B ZA 977263B
Authority
ZA
South Africa
Prior art keywords
treatment
upper airway
allergic responses
airway allergic
responses
Prior art date
Application number
ZA9707263A
Other languages
English (en)
Inventor
William Kreutner
John A Hey
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA977263B publication Critical patent/ZA977263B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA9707263A 1996-08-16 1997-08-13 Treatment of upper airway allergic responses. ZA977263B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68995196A 1996-08-16 1996-08-16

Publications (1)

Publication Number Publication Date
ZA977263B true ZA977263B (en) 1998-02-16

Family

ID=24770500

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9707263A ZA977263B (en) 1996-08-16 1997-08-13 Treatment of upper airway allergic responses.

Country Status (25)

Country Link
EP (1) EP0920315B1 (pl)
JP (2) JP3638289B2 (pl)
KR (1) KR20000029975A (pl)
CN (1) CN1152682C (pl)
AR (1) AR008293A1 (pl)
AT (1) ATE314071T1 (pl)
AU (1) AU722040B2 (pl)
BR (1) BR9711149A (pl)
CA (1) CA2263163A1 (pl)
CO (1) CO4910138A1 (pl)
CZ (1) CZ43299A3 (pl)
DE (1) DE69734984D1 (pl)
HU (1) HUP9904362A3 (pl)
ID (1) ID17871A (pl)
IL (1) IL128573A0 (pl)
MY (1) MY116130A (pl)
NO (1) NO990706D0 (pl)
NZ (1) NZ334063A (pl)
PE (1) PE100298A1 (pl)
PL (1) PL191073B1 (pl)
SK (1) SK20099A3 (pl)
TR (1) TR199900326T2 (pl)
TW (2) TW200427450A (pl)
WO (1) WO1998006394A1 (pl)
ZA (1) ZA977263B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2284705A1 (en) * 1997-03-26 1998-10-01 Sepracor Inc. Chemically and thermally stable norastemizole formulations
NZ501248A (en) * 1997-08-26 2001-06-29 Aventis Pharma Inc Pharmaceutical composition for combination of piperidinoalkanol-decongestant
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
EP1028948B1 (en) * 1997-11-07 2003-01-29 Schering Corporation Phenyl-alkyl-imidazoles as h3 receptor antagonists
US6034251A (en) * 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
WO1999024405A1 (en) * 1997-11-07 1999-05-20 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
JP2001522845A (ja) * 1997-11-07 2001-11-20 シェーリング コーポレイション １個の窒素原子を含有する５、６、または７員複素環式環で置換されたイミダゾイルアルキル
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
JP2002527381A (ja) * 1998-10-09 2002-08-27 シェーリング コーポレイション アレルギー性疾患を処置するための組成物および方法
US6100279A (en) * 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
CA2383214A1 (en) * 1999-09-22 2001-03-29 Schering Corporation Treating allergic and inflammatory conditions
WO2001056571A1 (en) * 2000-02-03 2001-08-09 Schering Corporation Treating allergic and inflammatory conditions
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
MXPA03008356A (es) 2001-03-13 2003-12-11 Schering Corp Compuestos del tipo no imidazol como antagonistas de histamina h3.
MXPA04010172A (es) 2002-04-18 2005-02-03 Schering Corp 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3).
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
DE60309598T2 (de) 2002-06-24 2007-09-13 Schering Corp. Als histamin-h3-antagonisten geeignete indolderivate
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
JP2008546784A (ja) 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
CA2739491A1 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
WO2010071822A1 (en) 2008-12-19 2010-06-24 Schering Corporation Piperidine and piperazine derivatives and methods of use thereof
EP2379564A1 (en) 2008-12-19 2011-10-26 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
CA2755679C (en) 2009-03-17 2017-09-12 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
CN107582551A (zh) * 2009-05-14 2018-01-16 总医院公司 治疗退化性及缺血性疾病的方法和组合物
EP2485735B1 (en) 2009-10-08 2015-07-29 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (fabp)
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
RU2685277C1 (ru) * 2018-05-24 2019-04-17 Общество с ограниченной ответственностью "Фарминтерпрайсез Аллерджи" Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201683B (en) * 1987-08-04 1990-12-28 Biogal Gyogyszergyar Process for producing pharmaceutical compositions for promoting healing of wounds
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
GB9303210D0 (en) * 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment

Also Published As

Publication number Publication date
PE100298A1 (es) 1999-01-11
NZ334063A (en) 2000-09-29
CO4910138A1 (es) 2000-04-24
IL128573A0 (en) 2000-01-31
PL331617A1 (en) 1999-08-02
TR199900326T2 (xx) 1999-05-21
CA2263163A1 (en) 1998-02-19
JP3638289B2 (ja) 2005-04-13
ATE314071T1 (de) 2006-01-15
NO990706L (no) 1999-02-15
PL191073B1 (pl) 2006-03-31
JP2000505094A (ja) 2000-04-25
JP2003095979A (ja) 2003-04-03
NO990706D0 (no) 1999-02-15
ID17871A (id) 1998-02-05
CN1152682C (zh) 2004-06-09
CN1233179A (zh) 1999-10-27
DE69734984D1 (de) 2006-02-02
MY116130A (en) 2003-11-28
EP0920315A1 (en) 1999-06-09
AR008293A1 (es) 1999-12-29
CZ43299A3 (cs) 1999-07-14
EP0920315B1 (en) 2005-12-28
KR20000029975A (ko) 2000-05-25
WO1998006394A1 (en) 1998-02-19
HUP9904362A3 (en) 2000-12-28
AU722040B2 (en) 2000-07-20
SK20099A3 (en) 2000-08-14
BR9711149A (pt) 1999-08-17
TWI221768B (en) 2004-10-11
HUP9904362A2 (hu) 2000-11-28
TW200427450A (en) 2004-12-16
AU3973397A (en) 1998-03-06

Similar Documents

Publication Publication Date Title
AU7905894A (en) Treatment of poultry
ZA966240B (en) Methods for treatment of allergic asthma.
IL128850A0 (en) Medical treatment
AU2058697A (en) Treatment of sleep disorders
ZA979731B (en) Treatment of asthma.
AU3552697A (en) Novel treatment of leptine resistance
GB9410512D0 (en) Novel treatment
ZA971607B (en) Methods of treatment of allergic diseases
GB9411635D0 (en) Novel treatment
GB9415901D0 (en) Novel compounds and treatment
ZA953237B (en) Medical treatment
GB9608657D0 (en) Novel treatment
GB9415900D0 (en) Novel compounds and treatment
IL119282A0 (en) Treatment of fowl
GB9411632D0 (en) Novel treatment
GB2324962B (en) Treatment of allergic conditions
GB9618290D0 (en) Treatment of diabetes
GB9709451D0 (en) Treatment of allergic conditions
IL127906A0 (en) Novel treatment of leptine resistance
GB9604008D0 (en) Treatment couch
GB9602404D0 (en) Methods of treatment
GB9609897D0 (en) Treatment of diabetes
GB9604916D0 (en) Treatment of lead
HK1020683A (en) Novel treatment of leptine resistance
HUP9902845A3 (en) Novel treatment of leptine resistance